Post
of 161,750
From ChatGPT, a better release
CytoDyn Reports New Leronlimab Data Demonstrating Immune Modulation and Long-Term Survival Signals in Metastatic Triple-Negative Breast Cancer at AACR 2026
Data highlight CCR5 inhibition as a potential strategy to enhance immunotherapy responsiveness in heavily pretreated mTNBC patients
VANCOUVER, Washington, April 20, 2026 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB: CYDY), a clinical-stage biotechnology company developing leronlimab, a humanized monoclonal antibody targeting the CCR5 receptor, today announced new clinical and translational data in metastatic triple-negative breast cancer (mTNBC) presented at the AACR Annual Meeting 2026 in San Diego, California (April 17–22).
The findings provide evidence that CCR5 inhibition with leronlimab may modulate the tumor microenvironment, increase PD-L1 expression, and enhance responsiveness to immune checkpoint inhibitors (ICIs)—an approach that could address a critical unmet need in mTNBC, an aggressive cancer subtype with limited treatment options.
Key Highlights
CCR5 linked to immune dysfunction: Analysis of 1,096 breast cancer samples showed CCR5 expression correlates with T-cell exhaustion and immune infiltration signatures.
Enrichment in TNBC subtypes: Elevated CCR5 expression was observed in immunomodulatory TNBC subtypes, including MLIA and IM.
PD-L1 induction observed: In preclinical TNBC models, leronlimab increased PD-L1 expression, suggesting potential to sensitize tumors to checkpoint inhibitors.
Immune suppression pathways reduced: CCR5 inhibition decreased expression of immune checkpoint mediators including sB7-H3 (CD276) and Tyro3 signaling.
Clinical signals in heavily pretreated patients: In a retrospective cohort of 28 mTNBC patients, leronlimab treatment was associated with PD-L1 induction in circulating tumor cells and macrophage-like cells.
Survival outcomes: Higher dosing and use alongside ICIs were associated with improved survival; notably, 17.9% (5/28) of patients remain alive beyond 60 months.
Scientific and Clinical Context
Metastatic triple-negative breast cancer is characterized by poor prognosis and limited therapeutic durability. While immune checkpoint inhibitors have improved outcomes in select patients, many tumors exhibit low PD-L1 expression and resistance to immunotherapy.
The data presented at AACR suggest that CCR5 may play a central role in immune exhaustion and resistance pathways. By inducing PD-L1 expression and reducing immune suppressive signaling, leronlimab may help convert immunologically “cold” tumors into more responsive ones.
“These findings support CCR5 as a regulator of immune suppression in TNBC and suggest that leronlimab may enhance sensitivity to checkpoint inhibition,” said Richard G. Pestell, M.D., Ph.D.
“We observed PD-L1 induction alongside reductions in key suppressive pathways, which may have important implications for combination immunotherapy strategies.”
Jacob P. Lalezari, M.D., Chief Executive Officer of CytoDyn, added:
“The association between PD-L1 induction, dosing, and long-term survival in heavily pretreated patients reinforces our development strategy for leronlimab in combination with immunotherapy. We believe these data support continued advancement into combination clinical studies in mTNBC.”
Presentation Details
The data were presented in a poster titled:
“Leronlimab induces PD-L1 expression and is associated with long-term survival with an ICI in PD-L1-low metastatic TNBC”
Presented April 19, 2026 (Poster #1033)
A copy of the poster will be available on the Company’s website under Publications & Posters.
What’s improved (quick rationale)
Stronger, more concise headline (less jargon, more impact)
Clear “why it matters” framing early
Reduced repetition of TNBC definition
Cleaner bullet points for readability
Tighter executive quotes (less dense, more quotable)
Balanced tone (credible, not promotional or overstated)
If you want, I can:
Make a more aggressive, investor-hype version (for retail buzz)
Or a more conservative, regulatory-safe version (for SEC scrutiny)
Or tailor it for biotech analysts vs. general media
CytoDyn Reports New Leronlimab Data Demonstrating Immune Modulation and Long-Term Survival Signals in Metastatic Triple-Negative Breast Cancer at AACR 2026
Data highlight CCR5 inhibition as a potential strategy to enhance immunotherapy responsiveness in heavily pretreated mTNBC patients
VANCOUVER, Washington, April 20, 2026 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB: CYDY), a clinical-stage biotechnology company developing leronlimab, a humanized monoclonal antibody targeting the CCR5 receptor, today announced new clinical and translational data in metastatic triple-negative breast cancer (mTNBC) presented at the AACR Annual Meeting 2026 in San Diego, California (April 17–22).
The findings provide evidence that CCR5 inhibition with leronlimab may modulate the tumor microenvironment, increase PD-L1 expression, and enhance responsiveness to immune checkpoint inhibitors (ICIs)—an approach that could address a critical unmet need in mTNBC, an aggressive cancer subtype with limited treatment options.
Key Highlights
CCR5 linked to immune dysfunction: Analysis of 1,096 breast cancer samples showed CCR5 expression correlates with T-cell exhaustion and immune infiltration signatures.
Enrichment in TNBC subtypes: Elevated CCR5 expression was observed in immunomodulatory TNBC subtypes, including MLIA and IM.
PD-L1 induction observed: In preclinical TNBC models, leronlimab increased PD-L1 expression, suggesting potential to sensitize tumors to checkpoint inhibitors.
Immune suppression pathways reduced: CCR5 inhibition decreased expression of immune checkpoint mediators including sB7-H3 (CD276) and Tyro3 signaling.
Clinical signals in heavily pretreated patients: In a retrospective cohort of 28 mTNBC patients, leronlimab treatment was associated with PD-L1 induction in circulating tumor cells and macrophage-like cells.
Survival outcomes: Higher dosing and use alongside ICIs were associated with improved survival; notably, 17.9% (5/28) of patients remain alive beyond 60 months.
Scientific and Clinical Context
Metastatic triple-negative breast cancer is characterized by poor prognosis and limited therapeutic durability. While immune checkpoint inhibitors have improved outcomes in select patients, many tumors exhibit low PD-L1 expression and resistance to immunotherapy.
The data presented at AACR suggest that CCR5 may play a central role in immune exhaustion and resistance pathways. By inducing PD-L1 expression and reducing immune suppressive signaling, leronlimab may help convert immunologically “cold” tumors into more responsive ones.
“These findings support CCR5 as a regulator of immune suppression in TNBC and suggest that leronlimab may enhance sensitivity to checkpoint inhibition,” said Richard G. Pestell, M.D., Ph.D.
“We observed PD-L1 induction alongside reductions in key suppressive pathways, which may have important implications for combination immunotherapy strategies.”
Jacob P. Lalezari, M.D., Chief Executive Officer of CytoDyn, added:
“The association between PD-L1 induction, dosing, and long-term survival in heavily pretreated patients reinforces our development strategy for leronlimab in combination with immunotherapy. We believe these data support continued advancement into combination clinical studies in mTNBC.”
Presentation Details
The data were presented in a poster titled:
“Leronlimab induces PD-L1 expression and is associated with long-term survival with an ICI in PD-L1-low metastatic TNBC”
Presented April 19, 2026 (Poster #1033)
A copy of the poster will be available on the Company’s website under Publications & Posters.
What’s improved (quick rationale)
Stronger, more concise headline (less jargon, more impact)
Clear “why it matters” framing early
Reduced repetition of TNBC definition
Cleaner bullet points for readability
Tighter executive quotes (less dense, more quotable)
Balanced tone (credible, not promotional or overstated)
If you want, I can:
Make a more aggressive, investor-hype version (for retail buzz)
Or a more conservative, regulatory-safe version (for SEC scrutiny)
Or tailor it for biotech analysts vs. general media
2